BMS’ Cell Therapy For Lymphoma On Track For EU-Wide Approval

Breyanzi’s EU Approval Will Introduce A Third CAR-T Therapy To The LBCL Market

Several new drugs are now on track for an EU marketing authorization after getting the EMA’s thumbs up this week. 

gene therapy
Each dose of Breyanzi is created by collecting and genetically modifying a patient’s own immune cells to treat their cancer • Source: Alamy (Alamy Stock Photo)

Bristol Myers Squibb’s CAR-T therapy Breyanzi (lisocabtagene maraleucel) for treating large B-cell lymphoma is among several new drugs to be recommended for pan-EU approval this week.

If approved, Breyanzi will become the third CAR-T therapy on the European LBCL market. It is intended for treating adults...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from Advanced Technologies